New combo shows promise for High-Risk leukemia patients

NCT ID NCT02688140

Completed Disease control Sponsor: Technische Universität Dresden Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested a new treatment for adults with a high-risk form of acute promyelocytic leukemia (APL). The experimental therapy combined arsenic trioxide, ATRA, and a low dose of idarubicin, aiming to improve survival and reduce side effects compared to the standard chemotherapy regimen. The trial enrolled 133 patients across Europe to see if this approach leads to better outcomes and quality of life.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE PROMYELOCYTIC LEUKEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute promyelocytic leukemia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ACUTE PROMYELOCYTIC LEUKEMIA

Contacts and locations

Show contact details

Locations

AML-CG study group

All Participating Sites, Germany
AML-SG study group

All Participating Sites, Germany
French-Belgian-Swiss APL study group

All Participating Sites, France
GIMEMA study group

All Participating Sites, Italy
HOVON study group

All Participating Sites, Netherlands
OSHO study group

All Participating Sites, Germany
PETHEMA study group

All Participating Sites, Spain
SAL study group

All Participating Sites, Germany